Search

In the gait recognition problem, most studies are devoted to developing gait descriptors rather than introducing new classification methods. This paper proposes hybrid methods that combine regularized discriminant analysis (RDA) and swarm intelligence techniques for gait recognition. The purpose of this study is to develop strategies that will achieve better gait recognition results than those achieved by classical classification methods. In our approach, particle swarm optimization (PSO), grey wolf optimization (GWO), and whale optimization algorithm (WOA) are used. These techniques tune the observation weights and hyperparameters of the RDA method to minimize the objective function. The experiments conducted on the GPJATK dataset proved the validity of the proposed concept.

This paper presents an evaluation of the annual cycle for 400 m hurdles using artificial neural networks. The analysis included 21 Polish national team hurdlers. In planning the annual cycle, 27 variables were used, where 5 variables describe the competitor and 22 variables represent the training loads. In the presented solution, the task of generating training loads for the assumed result were considered. The neural models were evaluated by cross-validation method. The smallest error was obtained for the radial basis function network with nine neurons in the hidden layer. The performed analysis shows that at each phase of training the structure of training loads is different.

The time-resolved photothermal methods are used in order to establish the yield of intersystem (singlet-triplet) crossing of dyes that are candidates for the application in photodynamic therapy. It is known that molecules with long living triplet state cause efficient photosensitization by direct interaction with the cells or by singlet oxygen generation.

It is estimated that seven key viruses such as Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-lymphotropic virus (HTLV), Human papilloma viruses (HPV), Kaposi’s sarcoma-associated herpes-virus (KSHV), Epstein-Barr virus (EBV) and Merkel cell polyomavirus (MCV), are responsible for about 11% of cancers all over the world. Viruses however are not only associated with cancerogenesis process. Scientific researches from recent years emphasize the possible use of the microorganisms as antitumor therapy. Oncoviruses, also defined as tumor viruses cause cancers whereas oncolytic viruses infect the host’s cancer cells leading to destruction of tumor and due to that they are described as cancer killing viruses. It offers the potential application of viral infections to the cancer therapy.

Over the last decade the availability of biological drugs for the treatment of psoriasis vulgaris, psoriatic arthritis and many other inflammatory diseases has revolutionized the treatment of these diseases around the world. Due to the high cost of therapy, the search has started for biosimilars. In dermatology the greatest interest in biosimilar medicines concerns inhibitors of tumor necrosis factor a (TNF-α), for use in the treatment of psoriasis vulgaris and psoriatic arthritis (infliximab, etanercept, adalimumab). The most important element of the safety of biologicals is their immunogenicity. Therefore, when discussing biosimilars, attention needs to be paid to the dangers of their immune activity. In view of the fact that the drugs contain and aggregates, produced by living organisms or cultures of living cells, they cannot be compared in any way to low molecular weight synthetic generics (called generics). Biosimilars are authorized for use in patients and treated as equivalent to the reference medicine only after passing a number of studies and assessments. As it is well known, the development of medicine and pharmacology is extremely intense, and the market in biological medicine is developing much faster than that of all other drugs, which underlines their important role in modern medicine. Currently, the subject of biosimilars is one of the most important challenges and topics of discussion around the world, including pharmacovigilance and legal and economic regulatory standards. It seems inevitable that biosimilar products will be introduced for the treatment of diseases with indications corresponding to the original product on which they are based.